PMC8080875_01
Changes in scalp hair on admission (A, B), 8 weeks (C, D) and 8 months after tofacitinib therapy (E, F).
fimmu-12-654376-g001.jpg
PMC8080875_01_fimmu-12-654376-g001.jpg
f1
Physical examination on admission revealed generalized rash with skin scratches and diffuse non-scarring alopecia involving nearly the entire scalp ( Figures 1A, B ). At 8 weeks, the methylprednisolone dose was reduced to 8 mg/day with no relapse of alopecia or rash ( Figures 1C, D ). At the time of writing this report (8 months after tofacitinib therapy was initiated), the patient was being treated with 5 mg/day tofacitinib combined with 4 mg/day methylprednisolone and 200 mg twice a day hydroxychloroquine, with stable hair regrowth ( Figures 1E, F ).